FDA classifies Alzheimer's test for easier patient access
Published Date: 4/22/2026
Rule
Summary
The FDA is officially putting the Alzheimer's Disease Pathology Assessment Test into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps make the test safer and easier to get to patients, starting April 22, 2026, with the classification retroactive to May 4, 2022. Doctors, patients, and device makers will benefit from faster access to this important tool without extra costs or delays.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Alzheimer's Test Reclassified to Class II
The FDA has classified the Alzheimer’s disease pathology assessment test as Class II (special controls), effective April 22, 2026, with the classification applicable retroactively to May 4, 2022. This means the test is subject to special safety rules but is in a lower device class than automatic Class III, which the FDA says will reduce regulatory burdens and enhance patient access.
Makes Future Devices Easier to Market
Because FDA classified this test via the De Novo process, this device can serve as a predicate for future devices, allowing other device sponsors to use the less burdensome 510(k) process rather than repeat De Novo or premarket approval steps. If you make or plan to make similar diagnostics, this should reduce regulatory time and burden for follow-on products.
This Test Still Requires a 510(k) Submission
The FDA states that Alzheimer's disease pathology assessment tests remain subject to premarket notification requirements under section 510(k) because FDA has not determined that the device type should be exempt under section 510(m). If you manufacture this test, you must submit a 510(k) to reasonably assure safety and effectiveness.
New Safety, Performance, and Labeling Requirements
The final order establishes special controls requiring detailed design verification and validation (e.g., precision, linearity, assay interference, cross-reactivity, detection capability, specimen and reagent stability, and hook effect), clinical performance studies documenting APOE status and PET tracer usage, and labeling that must state the test is not a stand-alone diagnostic and cannot predict dementia or monitor therapy. If you use or interpret this test, these controls aim to improve result accuracy and how results are communicated.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in